US Stock Market Move | Mineralys Therapeutics (MLYS.US) surges over 53% with the positive results of the release of hypertension drug research.
On Monday, Mineralys Therapeutics (MLYS.US) surged against the trend by over 53%, reaching $16.25.
On Monday, Mineralys Therapeutics (MLYS.US) surged more than 53% against the trend, reaching $16.25. In terms of news, the company reported positive preliminary results from two key studies of its Lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension on Monday. Mineralys stated that its Phase III Launch-HTN and Phase II Advance-HTN studies met pre-specified primary efficacy endpoints with statistical significance, showing clinical significance, and demonstrating good safety and tolerability.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
